NNovo Nordisk Read More India 2030: Who Supplies the Next 10 Million?2026-11-01 India 2030: Who Supplies the Next 10 Million? November 01, 2026 | Sunday | Features | By Ankit…
NNovo Nordisk Read More Novo Nordisk Navigates a Market Split: European Reimbursement Gains Offset by Generic Erosion in Eme2026-05-28 France to reimburse Wegovy from June, unlocking 1M patients, but generic Ozempic in Brazil, India, Canada erodes pricing…
NNovo Nordisk Read More Novo Nordisk’s Brazilian Generic Setback Adds Urgency to ADA Pipeline Showcase2026-05-28 Brazil approves first generic Ozempic at 30% discount; Novo cuts Canada prices. All eyes on CagriSema Phase 3…
NNovo Nordisk Read More Novo Nordisk Faces Crosswinds: EU Approvals and Heart Data Offset Brazil Generic Threat and Pricing2026-05-27 Novo Nordisk stock near €38 as Brazil OKs generic Ozempic, EU clears 2 Wegovy variants, CV study shows…
NNovo Nordisk Read More Novo Nordisk Balances Amazon Access and Generic Onslaught as Pipeline Decision Looms2026-05-17 Novo Nordisk’s stock is squeezed between a landmark Amazon Pharmacy distribution deal and pricing erosion from Indian generics…
NNovo Nordisk Read More Novo Nordisk Faces First Generic Challenge in Canada as Wegovy Oral Pill Dominates US Market2026-05-15 Novo Nordisk’s US Wegovy surges with 65% of new scripts, raising guidance, but Canadian Ozempic generic approval threatens…
NNovo Nordisk Read More Generic Competition Meets a Pipeline Showcase2026-05-01 Novo Nordisk enters a critical period with Q1 earnings due May 6, a Canadian Ozempic generic launch, stock…
NNovo Nordisk Read More Teen Pill Success Meets Canadian Generic Shock2026-04-30 Novo Nordisk celebrates positive trial results for oral semaglutide in teens while facing first generic Ozempic competition in…
NNovo Nordisk Read More Novo Nordisk’s Hemophilia Breakthrough Fails to Distract From Canadian Generic Blow2026-04-30 Novo Nordisk’s stock slides 41% as Canada approves first generic Ozempic, while promising hemophilia data fails to lift…
NNovo Nordisk Read More Canadian Generic Launch and Q1 Results Loom2026-04-29 Health Canada authorizes Dr. Reddy’s biosimilar semaglutide, threatening Novo Nordisk’s Ozempic revenue as share buyback reaches 3.44 billion…
NNovo Nordisk Read More Novo Nordisk Juggles Pipeline Advances and Generic Threat as Share Buyback Hits $3.44 Billion2026-04-29 Novo Nordisk launches Phase 3 knee OA trial, gains FDA fast-track for heart drug, as first Ozempic generic…
NNovo Nordisk Read More Novo Nordisk’s Teen Pill Breakthrough and Canadian Generic Blow Arrive in the Same Week2026-04-28 Novo Nordisk faces a historic Ozempic generic in Canada while scoring a first-in-class oral GLP-1 win for teens,…